跳至主要内容
临床试验/NL-OMON21014
NL-OMON21014已完成不适用

Intravenous immunoglobulin in the treatment of fetal or neonatal alloimmune thrombocytopenia. A prospective, multicentre, randomized trial comparing 0.5 g and 1.0 g IvIG per kilogram bodyweight per week.

Sanquin Bloodbank Amsterdam provides the trial medication0 个研究点目标入组 212 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
212

研究概览

简要总结

/A

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Pregnant women with a subsequent pregnancy after prior pregnancy complicated by HPA alloimmunization who have given birth to a child with a platelet count < 150 x 10 9/l in the first week of life;
  • 2. HPA alloimmunization must have been confirmed by the presence of maternal anti-HPA antibodies and the offending HPA antigen in the fetus or homozygous partner;

排除标准

  • 1. Pregnant women with autoimmune thrombocytopenia;
  • 2. Twins or multiple pregnancies;

研究者

发起方
Sanquin Bloodbank Amsterdam provides the trial medication

相似试验